NCT07138677

Brief Summary

Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 30, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

July 20, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 24, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

September 15, 2025

Status Verified

September 1, 2025

Enrollment Period

5 months

First QC Date

April 30, 2025

Last Update Submit

September 9, 2025

Conditions

Keywords

Alzheimer's DiseaseTranscranial Magnetic StimulationIndividualized navigation

Outcome Measures

Primary Outcomes (1)

  • Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog)

    The changes in Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog) will constitute the major research outcome measure used to assess response to transcranial magnetic stimulation (TMS). The ADAS-COG scale tests orientation, language, structure, use of ideas, immediate recall of words and word re-recognition, and consists of 11 questions out of a possible 70 points, with the higher the score the more cognitively impaired.

    Baseline and 2 weeks

Secondary Outcomes (12)

  • Mini Mental State Examination (MMSE)

    Baseline and 2 weeks

  • Montreal Cognitive Assessment (MoCA)

    Baseline and 2 weeks

  • Digital Span Test; Forward and Backward (DST)

    Baseline and 2 weeks

  • Hamilton Depression Scale (HAMD)

    Baseline and 2 weeks

  • Hamilton Anxiety Scale (HAMA)

    Baseline and 2 weeks

  • +7 more secondary outcomes

Study Arms (2)

MCI real group

EXPERIMENTAL

Stimulation delivered by a real coil through MagStim Rapid2 and guided by BrainSight navigation system.

Other: transcranial magnetic stimulation

MCI sham group

SHAM COMPARATOR

Stimulation delivered by a sham coil through MagStim Rapid2 and guided by BrainSight navigation system.

Other: transcranial magnetic stimulation

Interventions

Neuronavigated Theta-Burst Transcranial Magnetic Stimulation

MCI real groupMCI sham group

Eligibility Criteria

Age45 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria.
  • MMSE score 18-28.
  • CDR score 0.5-1.
  • On stable treatment with IAChE or memantine for at least 6 months.
  • Literate in Han Chinese.

You may not qualify if:

  • Recevied rTMS treatment in the past 3 months.
  • Depression or other psychiatric disorders.
  • History of head injury, stroke, epilepsy or other neurologic disease.
  • Organic brain defects on T1 or T2 images.
  • History of unexplained loss of consciousness.
  • Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI.
  • Family history of medication refractory epilepsy.
  • History of substance abuse within the last 6 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anhui Medical University

Hefei, Anhui, 230000, China

RECRUITING

MeSH Terms

Interventions

Transcranial Magnetic Stimulation

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of medical psychological department, Anhui Medical University

Study Record Dates

First Submitted

April 30, 2025

First Posted

August 24, 2025

Study Start

July 20, 2025

Primary Completion

December 30, 2025

Study Completion

December 30, 2025

Last Updated

September 15, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations